Ofev scores funding in the UK for ultra-rare lung disease

A positive reimbursement decision in the UK will see patients in England and Wales gain access to Boehringer Ingelheim’s Ofev (nintedanib) through the country’s national healthcare provider.

In its final appraisal decision, the National Institute for Health and Care Excellence (NICE) said it was recommending the treatment for adults with chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILD).

ILD is a diverse range of lung disorders, typically involving progressive fibrosing, and people with PF-ILD typically have progressive scarring of interstitial lung tissue.